BRISTOL MYERS SQUIBB
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
BMS-599626 in Patients With Advanced Solid Malignancies
- First Posted Date
- 2004-11-08
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 60
- Registration Number
- NCT00095537
- Locations
- 🇺🇸
Local Institution, Los Angeles, California, United States
Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-11-04
- Last Posted Date
- 2011-04-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 645
- Registration Number
- NCT00095394
- Locations
- 🇷🇺
Local Institution, St. Petersburg, Russian Federation
Irbesartan Versus Placebo in Combination With Ramipril for Treatment of Albuminuria
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-11-03
- Last Posted Date
- 2011-04-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 400
- Registration Number
- NCT00095290
- Locations
- 🇬🇧
Local Institution, Derby, West Midlands, United Kingdom
BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis
- First Posted Date
- 2004-11-02
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 214
- Registration Number
- NCT00095173
- Locations
- 🇨🇭
Local Institution, Lausanne, Switzerland
Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve)
- First Posted Date
- 2004-11-02
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 4128
- Registration Number
- NCT00095238
- Locations
- 🇬🇧
Local Institution, Londonderry, United Kingdom
Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis
- First Posted Date
- 2004-11-02
- Last Posted Date
- 2015-03-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 431
- Registration Number
- NCT00095147
- Locations
- 🇨🇭
Local Institution, St. Gallen, Switzerland
Mechanism of Action and Efficacy of Muraglitazar in Type 2 Diabetes
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-11-01
- Last Posted Date
- 2010-09-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 42
- Registration Number
- NCT00094991
- Locations
- 🇮🇹
Local Institution, Pisa, Italy
Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-11-01
- Last Posted Date
- 2010-09-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1752
- Registration Number
- NCT00095030
- Locations
- 🇹🇭
Local Institution, Bangkok, Thailand
MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-10-22
- Last Posted Date
- 2011-07-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1783
- Registration Number
- NCT00094653
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Study of Boosted Atazanavir (ATV) Versus Non-boosted ATV in Naive Patients
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2010-03-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 200
- Registration Number
- NCT00084253
- Locations
- 🇺🇸
Various locations within the US, Call for Information, New Jersey, United States
© Copyright 2024. All Rights Reserved by MedPath